MedPath

Validation of a CDSA Strategy to Reduce Antibiotic Prescription in Senegal

Not Applicable
Conditions
Malaria
Dengue
Pneumonia
Diarrhea
Acute Febrile Illness
Influenza -Like Illness
Interventions
Other: Patient clinical management based on the CDSA strategy
Registration Number
NCT05050825
Lead Sponsor
Foundation for Innovative New Diagnostics, Switzerland
Brief Summary

This trial aims to validate a novel clinical care strategy based on a electronic clinical decision support algorithm (CDSA) combined with point of care rapid diagnostic tests by evaluating its impact on antibiotic prescription and clinical outcome of children and adolescent presenting at primary healthcare facilities with non-severe acute illness compared to routine practice. The trial also aims to assess the usability of the CDSA strategy. The study will be conducted in primary healthcare facilities across different epidemiological regions of Senegal.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
470
Inclusion Criteria
  • Ongoing fever or diarrhea
  • ongoing fever will be defined objectively or as a reported fever, defined as : axillary temperature ≥37.5°C or tympanic, oral or rectal temperature ≥38.0°C; and fever duration ≤ 10 days
  • ongoing diarrhea will be defined as at least 3 abnormal stools during the last 24hrs
  • First consultation for the current illness
  • Feasibility of contact between the patient (or his/her designated relative) and the study team at day 3 and day 7
  • Written informed consent by the caretaker/legally acceptable representative
Exclusion Criteria
  • Infants less than 6 months of age
  • Age ≥ 15 years
  • Clinical status requiring immediate transfer to an appropriate care facility/ severe illness

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CDSA strategyPatient clinical management based on the CDSA strategyChildren and adolescents presenting with non-severe acute febrile illness or diarrhea managed by healthcare workers trained on the CDSA strategy
Primary Outcome Measures
NameTimeMethod
Non-inferiority of the CDSA strategy when compared to routine practice in terms of clinical status assessed at Day 74 months

This will be measured as point estimates of the percent change of patient with resolved illness at Day 7 in the intervention arm, as compared to the control arm.

Superiority of the CDSA strategy when compared to routine practice in terms of antibiotic prescription at Day 04 months

This will be measured as point estimates of the percent change of antibiotic prescription at Day 0 in the intervention arm, as compared to the control arm and to site-specific historical data. This measure aims to assess rational use of antibiotics using the CDSA strategy compared to routine practice.

Secondary Outcome Measures
NameTimeMethod
Diagnostic performance of the dengue rapid diagnostic test (RDT)4 months

The performance of the dengue RDT used in health facilities will be assessed against reference standards.

Antibiotic prescription rate during 7 days of follow-up in the intervention arm compared to the control arm4 months

This measure will further assess rational antibiotic prescribing using the CDSA strategy compared to routine practice.

Identification of risk factors associated with viral and bacterial infections4 months

This measure aims to better characterize viral and bacterial infections in children and adolescents presenting with acute illness in these settings and improve the next version of the algorithm.

Trial Locations

Locations (4)

PS Ndiaye-Fatick

🇸🇳

Fatick, Senegal

PS Kedougou-Dalaba

🇸🇳

Kedougou, Senegal

PS Mbour-Toucouleur

🇸🇳

Mbour, Senegal

PS Pont-Tambacounda

🇸🇳

Tambacounda, Senegal

© Copyright 2025. All Rights Reserved by MedPath